Clinical Trial Update: An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication [Phase 3]

View source ↗

Summary

This document reports results from an extension Phase 3 study of SEP-363856 in schizophrenia. It examines effectiveness and safety when patients switch from the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• SEP-363856

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2025-11-12